ING Group’s Zimmer Biomet ZBH Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q1 | – | Sell |
-93,026
| Closed | -$9.83M | – | 620 |
|
|
2024
Q4 | $9.83M | Buy |
93,026
+76,389
| +459% | +$8.2M | 0.07% | 196 |
|
|
2024
Q3 | $1.8M | Sell |
16,637
-90,246
| -84% | -$9.85M | 0.01% | 431 |
|
|
2024
Q2 | $11.6M | Buy |
+106,883
| New | +$12.6M | 0.07% | 206 |
|
|
2024
Q1 | – | Sell |
-56,010
| Closed | -$6.82M | – | 632 |
|
|
2023
Q4 | $6.82M | Sell |
56,010
-55,224
| -50% | -$6.16M | 0.05% | 252 |
|
|
2023
Q3 | $12.5M | Buy |
111,234
+82,140
| +282% | +$10.4M | 0.11% | 175 |
|
|
2023
Q2 | $4.24M | Sell |
29,094
-3,538
| -11% | -$481K | 0.03% | 275 |
|
|
2023
Q1 | $4.22M | Buy |
32,632
+10,083
| +45% | +$1.27M | 0.04% | 270 |
|
|
2022
Q4 | $2.87M | Buy |
+22,549
| New | +$2.62M | 0.03% | 314 |
|
|
2022
Q3 | – | Sell |
-2,521
| Closed | -$265K | – | 557 |
|
|
2022
Q2 | $265K | Buy |
+2,521
| New | +$299K | ﹤0.01% | 520 |
|
|
2022
Q1 | – | Sell |
-28,084
| Closed | -$3.46M | – | 617 |
|
|
2021
Q4 | $3.46M | Buy |
28,084
+10,025
| +56% | +$1.31M | 0.03% | 351 |
|
|
2021
Q3 | $2.57M | Buy |
18,059
+422
| +2% | +$62.1K | 0.03% | 311 |
|
|
2021
Q2 | $2.75M | Buy |
17,637
+3,462
| +24% | +$561K | 0.04% | 250 |
|
|
2021
Q1 | $2.2M | Buy |
14,175
+14
| +0.1% | +$2.17K | 0.05% | 233 |
|
|
2020
Q4 | $2.12M | Buy |
14,161
+9,442
| +200% | +$1.33M | 0.05% | 236 |
|
|
2020
Q3 | $624K | Buy |
4,719
+2,918
| +162% | +$381K | 0.03% | 257 |
|
|
2020
Q2 | $209K | Sell |
1,801
-2,071
| -53% | -$239K | 0.01% | 273 |
|
|
2020
Q1 | $380K | Sell |
3,872
-10,659
| -73% | -$1.4M | 0.02% | 276 |
|
|
2019
Q4 | $2.11M | Buy |
+14,531
| New | +$2.01M | 0.06% | 201 |
|
|
2019
Q3 | – | Sell |
-7,139
| Closed | -$816K | – | 774 |
|
|
2019
Q2 | $816K | Buy |
+7,139
| New | +$836K | 0.01% | 419 |
|
|
2019
Q1 | – | Sell |
-24,433
| Closed | -$2.46M | – | 834 |
|
|
2018
Q4 | $2.46M | Buy |
24,433
+21,083
| +629% | +$2.37M | 0.05% | 205 |
|
|
2018
Q3 | $428K | Sell |
3,350
-10,228
| -75% | -$1.22M | 0.01% | 556 |
|
|
2018
Q2 | $1.47M | Buy |
13,578
+1,655
| +14% | +$180K | 0.03% | 257 |
|
|
2018
Q1 | $1.26M | Buy |
+11,923
| New | +$1.38M | 0.02% | 283 |
|
|
2017
Q3 | – | Sell |
-15,935
| Closed | -$1.99M | – | 925 |
|
|
2017
Q2 | $1.99M | Buy |
+15,935
| New | +$1.89M | 0.04% | 217 |
|
|
2017
Q1 | – | Sell |
-17,206
| Closed | -$1.73M | – | 625 |
|
|
2016
Q4 | $1.73M | Buy |
+17,206
| New | +$1.84M | 0.03% | 232 |
|
|
2016
Q2 | – | Sell |
-4,267
| Closed | -$442K | – | 613 |
|
|
2016
Q1 | $442K | Sell |
4,267
-131,125
| -97% | -$12.7M | 0.01% | 392 |
|
|
2015
Q4 | $13.5M | Sell |
135,392
-4,792
| -3% | -$469K | 0.08% | 201 |
|
|
2015
Q3 | $12.8M | Buy |
140,184
+1,095
| +0.8% | +$110K | 0.09% | 180 |
|
|
2015
Q2 | $14.7M | Buy |
139,089
+78,716
| +130% | +$8.71M | 0.08% | 205 |
|
|
2015
Q1 | $6.88M | Buy |
60,373
+51,610
| +589% | +$5.89M | 0.03% | 328 |
|
|
2014
Q4 | $965K | Buy |
8,763
+6,640
| +313% | +$700K | ﹤0.01% | 579 |
|
|
2014
Q3 | $207K | Sell |
2,123
-420
| -17% | -$41.3K | ﹤0.01% | 628 |
|
|
2014
Q2 | $256K | Hold |
2,543
| – | – | ﹤0.01% | 618 |
|
|
2014
Q1 | $234K | Sell |
2,543
-561
| -18% | -$51.7K | ﹤0.01% | 655 |
|
|
2013
Q4 | $281K | Buy |
3,104
+20
| +0.6% | +$1.73K | ﹤0.01% | 628 |
|
|
2013
Q3 | $246K | Buy |
3,084
+371
| +14% | +$29.2K | ﹤0.01% | 666 |
|
|
2013
Q2 | $197K | Buy |
+2,713
| New | +$203K | ﹤0.01% | 659 |
|
Other funds holding ZBH
ING Group's ZBH Position: Q1 2025 in Review
ING Group sold out of Zimmer Biomet (ZBH) in Q1 2025, closing a stake of 93,026 shares — an estimated $9.83M sold.
ING Group first reported a position in ZBH in Q2 2013 and held it in 37 quarters. The position peaked at $14.7M in Q2 2015. 1,000 funds tracked by Wall St. Rank hold ZBH as of Q1 2025.
- ING Group reported no remaining Zimmer Biomet position as of Q1 2025 after selling out during the quarter.
- ING Group sold 93,026 Zimmer Biomet shares in Q1 2025, an estimated $9.83M.
- ING Group first reported a position in Zimmer Biomet in Q2 2013 and held it in 37 quarters.
- ING Group's Zimmer Biomet position peaked at $14.7M in Q2 2015.
- 1,000 funds tracked by Wall St. Rank held Zimmer Biomet as of Q1 2025.
Based on ING Group's 13F filing for Q1 2025, filed 9 May 2025.